bispecific therapeutics

Oncology

For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?

News

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc.

News

Johnson & Johnson's multiple myeloma regimen is now approved as a second line treatment in both the US and the EU.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.